Follicular Lymphoma

Follicular lymphoma is one of the most common kinds of non-Hodgkin lymphoma. Its progression rate varies widely, though it tends to spread slowly and has few symptoms. Patients with follicular lymphoma usually survive ten years or longer.

What is Follicular Lymphoma?

Follicular lymphoma is a cancer of the B-cells that accounts for around one third of all cases of lymphoma. The cancer is a form of non-Hodgkin lymphoma that usually affects adults, with an average age-at-diagnosis of 60. Follicular lymphoma is more common among women than among men.

Follicular Lymphoma Causes

Follicular Lymphoma Treatments

Relapsed/Refractory Follicular Lymphoma

Relapsed/Refractory Follicular Lymphoma Support

Relapsed/Refractory Follicular Lymphoma Prognosis and Epidemiology

Relapsed/Refractory Follicular Lymphoma Causes

Relapsed/Refractory Follicular Lymphoma Response Evaluation

Relapsed/Refractory Follicular Lymphoma and Personalized Medicine

Relapsed/Refractory Follicular Lymphoma Treatment

Latest Follicular Lymphoma News and Research

Yale and AI Therapeutics launch clinical trial of potential COVID-19 drug

Yale School of Medicine and the biopharmaceutical firm AI Therapeutics have launched a multi-institutional clinical trial of a drug for treating COVID-19.

27 Jul 2020

Combining two immunotherapies into a single treatment found to be more effective

Some of the most promising advances in cancer treatment have centered on immunotherapies that rev up a patient's immune system to attack cancer. But immunotherapies don't work in all patients, and researchers have been searching for ways to increase their effectiveness.

23 Jul 2020

Study shows potential new approach to treating two common subtypes of lymphoma

A study at The University of Texas MD Anderson Cancer Center demonstrated a potential new approach to treating two of the most common subtypes of lymphoma through manipulation of molecular programs controlled by the cAMP-response element binding protein.

8 Jan 2020

Next-generation sequencing can detect genetic alterations specific to follicular lymphoma

People with follicular lymphoma, a slow-growing lymphatic-system cancer, who have been treated and are in remission for at least two years, may no longer have what has been considered an incurable disease based on highly sensitive testing.

9 Dec 2019

$Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission$

Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission

A new, experimental immunotherapy can put patients with B-cell non-Hodgkin lymphoma (NHL) that is resistant to or has come back after multiple other therapies, including CAR T therapy, into remission.

8 Dec 2019

Cancer patients share survivorship story, celebrate strength and self-care

To survive in his struggle against an aggressive form of prostate cancer, Bin McLaurin didn't only have to overcome the disease attacking his body. He said he also had to toss out his long-held image of masculinity.

16 Jun 2019

HCA Healthcare UK introduces ground-breaking new blood cancer treatment

HCA Healthcare UK has announced the launch of CAR T-cell therapy - a ground-breaking new blood cancer treatment which will be available to eligible patients with Diffuse Large B-Cell Lymphoma and Acute Lymphoblastic Leukaemia.

3 Apr 2019

T-cells play key role in how the body fights follicular lymphoma

Healthy white blood cells, called "T-cells," play a crucial role in how the body fights follicular lymphoma. That's according to the results of a study led by Mayo Clinic hematologists Zhi Zhang Yang, M.D., and Stephen Ansell, M.D., Ph.D., that was published in Cell Reports.

20 Feb 2019

CAR T therapy can lead to long-lasting remissions in patients with r/r diffuse large B-cell lymphoma

In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).

3 Dec 2018

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.

1 Nov 2018

Phase 2 results on tazemetostat EZH2 inhibitor to be presented at ESMO 2018

Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies, announced today that updated efficacy and safety data from the fully enrolled cohort of epithelioid sarcoma (ES) patients in its ongoing Phase 2 trial of tazemetostat will be presented in a poster discussion session at the European Society for Medical Oncology (ESMO) 2018 Congress to be held October 19-23 in Munich, Germany.

10 Oct 2018

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Verastem, Inc., focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network added COPIKTRA (duvelisib) capsules to the Clinical Practice Guidelines in Oncology (NCCN Guidelines) for follicular lymphoma.

8 Oct 2018

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, today announced that it has been selected by Verastem OncologyTM to dispense COPIKTRA (duvelisib) capsules.

28 Sep 2018

FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials

Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies, today announced the U.S. Food and Drug Administration has lifted the partial clinical hold that had paused U.S.-based enrollment of new patients in its tazemetostat clinical trials.

24 Sep 2018

Verastem doses first patient in Phase I/II clinical trial of duvelisib in combination with venetoclax

Verastem, Inc., operating as Verastem Oncology, a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced dosing of the first patient in a multicenter Phase I/II clinical trial at the Dana-Farber/Harvard Cancer Center of duvelisib in combination with venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

6 Sep 2018

Celgene to share new and updated data around novel hematological therapies

Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.

22 May 2018

New compounds targeting epigenetics show promise in lymphoma patients

New compounds targeting epigenetics have shown remarkable early activity in patients with lymphoma, according to data presented at the TAT (Targeted Anticancer Therapies) International Congress 2018 in Paris, France.

5 Mar 2018

Study reveals HCT as effective treatment for NHL patients regardless of age

Results from a retrospective study of 1,629 patients with non-Hodgkin lymphoma showed that survival at 4 years following allogeneic hematopoietic cell transplantation for patients age 65 years and older is comparable to patients age 55 to 64 years.

21 Feb 2018

CAR T cell therapy shows long-lasting remissions in non-Hodgkin's lymphoma patients

In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) patients.

11 Dec 2017

VICC selected to administer FDA-approved CAR T therapy for treatment of lymphoma patients

Vanderbilt-Ingram Cancer Center has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR T) therapy for treatment of adult patients with a specific type of lymphoma.

25 Oct 2017